



Volume 3, Issue 3
March 2024

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- Thyrotropin alfa (THYROGEN) Inj

Drugs Added to the VA National Formulary WITH Prior Authorization

- Nadofaragene firadenovec (ADSTILADRIN)
- Relugolix-estradiol-norethindrone (MYFEMBREE)
- Tremelimumab-actl (IMJUDO) for Hepatocellular Carcinoma

Drugs Not Added to the VA National Formulary

- Elagolix-estradiol-norethindrone (ORIAHNN)
- Mirikizumab-mrkz (OMVOH)
- Tick-borne encephalitis vaccine (TICOVAC)
- Zuranolone (ZURZUVAE)
- Albuterol-budesonide (AIRSUPRA) Inhaler

Formulary Drugs with Prior Authorization Removed

- Sodium zirconium cyclosilicate
- Patiomer

Drugs Removed from the VA National Formulary

- Alfentanil inj, soln: manufacturer discontinuation
- Apomorphine film, sublingual: manufacturer discontinuation
- Dimercaprol inj, soln: manufacturer discontinuation
- Ritonavir soln, oral: manufacturer discontinuation
- Saquinavir tab: manufacturer discontinuation

Other Announcements

- Bispecific Antibody CRS and ICANS Neurotoxicity Guidance created
- Secukinumab (COSENTYX) SC Injection in Hidradenitis Suppurativa Criteria for Use created
- Risankizumab (SKYRIZI) in Plaque Psoriasis Revised Criteria for Use - revised
- Istradefylline_NOURIANZ_Criteria for Use created
- Naloxone Rescue Guidance_March 2024 – Updated guidance document
- Buprenorphine for Chronic Pain_Mar 2024 – Updated guidance document
- Erdafitinib (BALVERSA) Criteria Rev Mar 2024 - Updated Criteria for Use
- Enfortumab vedotin PADCEV for Combination Therapy in Bladder Cancer Criteria Rev Mar 2024 - Updated Criteria for Use
- Elagolix ORILISSA Endometriosis Criteria for Use Mar 2024 created